title: Adherence to anti-Parkinson drug therapy in the "REASON" sample of Italian patients with Parkinson's disease: the linguistic validation of the Italian version of the "Morisky Medical Adherence Scale-8 items".
abstract: Information about patients' adherence to therapy represents a primary issue in Parkinson's disease (PD) management. To perform the linguistic validation of the Italian version of the self-rated 8-Item Morisky Medical Adherence Scale (MMAS-8) and to describe in a sample of Italian patients affected by PD the adherence to anti-Parkinson drug therapy and the association between adherence and some socio-demographic and clinical features. MMAS-8 was translated into Italian language by two independent Italian mother-tongue translators. The consensus version was then back-translated by an English mother-tongue translator. This translation process was followed by a consensus meeting between the authors of translation and investigators and then by two comprehension tests. The translated version of the MMAS-8 scale was then administered at the baseline visit of the "REASON" study (Italian Study on the Therapy Management in Parkinson's disease: Motor, Non-Motor, Adherence and Quality Of Life Factors) in a large sample of PD patients. The final version of the MMAS-8 was easily understood. Mean ± SD MMAS-8 score was 6.1 ± 1.2. There were no differences in adherence to therapy in relationship to disease severity, gender, educational level or decision to change therapy. The Italian version of MMAS-8, the key tool of the REASON study to assess the adherence to therapy, has shown to be understandable to patients with PD. Patients enrolled in the REASON study showed medium therapy adherence.
authors.affiliation: Sapienza University of Rome and IRCCS Neuromed Institute, Pozzilli (IS), Italy.
authors.forename: G
authors.initials: G
authors.lastname: Fabbrini
authors.forename: G
authors.initials: G
authors.lastname: Abbruzzese
authors.forename: P
authors.initials: P
authors.lastname: Barone
authors.forename: A
authors.initials: A
authors.lastname: Antonini
authors.forename: M
authors.initials: M
authors.lastname: Tinazzi
authors.forename: G
authors.initials: G
authors.lastname: Castegnaro
authors.forename: S
authors.initials: S
authors.lastname: Rizzoli
authors.forename: D E
authors.initials: DE
authors.lastname: Morisky
authors.forename: P
authors.initials: P
authors.lastname: Lessi
authors.forename: R
authors.initials: R
authors.lastname: Ceravolo
mesh_terms: D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D055118:Medication Adherence; D010300:Parkinson Disease / Q000188:drug therapy*; D011795:Surveys and Questionnaires; D014177:Translations
chemical_list: D000978:Antiparkinson Agents